Challenges for Treatment Trials of Inclusion Body Myositis

Affiliations

¹ From the Yale University School of Medicine (B.R.), New Haven, CT; and University of Rochester Medical Center (R.C.G.), NY. bhaskar.roy@yale.edu.
² From the Yale University School of Medicine (B.R.), New Haven, CT; and University of Rochester Medical Center (R.C.G.), NY.

Editorial

Bhaskar Roy et al. Neurology. 2021.

. 2021 Mar 23;96(12):555-556.

doi: 10.1212/WNL.0000000000011628. Epub 2021 Feb 17.

¹ From the Yale University School of Medicine (B.R.), New Haven, CT; and University of Rochester Medical Center (R.C.G.), NY. bhaskar.roy@yale.edu.
² From the Yale University School of Medicine (B.R.), New Haven, CT; and University of Rochester Medical Center (R.C.G.), NY.

No abstract available

Comment on

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.